Washington (April 8, 2025) - Senator Edward J. Markey (D-Mass.), top Democrat on the Small Business Committee, as well as the Health, Education, Labor, and Pensions (HELP) Subcommittee on Primary Health and Retirement Security, today hosted a virtual town hall with panelists from MassMEDIC, Conference of Boston Teaching Hospitals, VentureWell, Boyd Biomedical, and the Wyss Institute on the importance of protecting health care innovation and patient access to care in Massachusetts and across the country. Recent Trump administration actions threaten health care innovation and access in the United States and the Commonwealth, including cuts to research funding, disruptions in funding for health providers, and firing of employees at the Food and Drug Administration (FDA), National Institutes of Health (NIH), and Centers for Medicare and Medicaid Services (CMS).
“With President Trump’s and Congressional Republicans’ attacks on medical research, on health care access, on small businesses, and innovation, they are attacking Massachusetts,” said Senator Markey. “I heard stories from health care leaders, manufacturers, researchers, and patients that demonstrate what these reckless and indiscriminate tariffs, cuts to medical research and personnel, and efforts to gut Medicaid will mean for our ability to innovate affordable, accessible treatments and cures, and deliver high-quality care to patients in Massachusetts. I stand with them in the fight to protect life-saving research and care.”
Massachusetts is a national leader in developing groundbreaking treatments and cures, giving hope to patients, families, and caregivers in need of breakthroughs and discoveries. Massachusetts received nearly $3.5 billion in 2024 from the NIH to support 6,000 grants including for Alzheimer’s and youth mental health. Massachusetts received nine percent of National Institutes of Health funding in 2024 despite only having two percent of the population. Since its inception, Massachusetts has also received $26,000 from the Small Business Innovation Research (SBIR) program, totaling $9 billion in funding including for Alzheimer’s prevention, diagnosis and treatment and breast cancer detection. Committed health providers, researchers, and workers drive these innovations, relying on sustainable funding to do their work.
“On behalf of the region’s medical device sector, I thank Sen. Markey for his steadfast support of life science innovation and manufacturing. The Commonwealth’s economy depends on our ability to deliver new cures and treatments to the world. The senator is a great partner in developing federal policy that encourages growth and patient impact,” said Brian Johnson, President of MassMEDIC.
“The NIH continues to be our nation’s greatest hope for identifying life changing diagnostics, treatments, and cures, while supporting countless jobs, driving economic activity, and ensuring the United States’ position as a global leader in scientific research and medical innovation,” said Patricia McMullin, Executive Director of the Conference of Boston Teaching Hospitals. “We are grateful to Senator Markey and the entire Massachusetts congressional delegation for their advocacy to strengthen our nation’s medical research, which saves lives and gives hope to families across the nation and around the world.”
“The scientific breakthroughs of tomorrow and the health solutions that improve lives depend on sustained investment in foundational biomedical research and development funding. Agencies within the Department of Health and Human Services, including the National Institutes of Health (NIH) and the Advanced Research Projects Agency for Health (ARPA-H), play a critical role in enabling this progress. Continued funding and support ensure that discoveries can be translated into transformative products and services for patients,” said Mark Marino, Vice President at VentureWell. “Federal research investments in areas such as cancer, chronic disease, Alzheimer’s, mental health, environmental health, nutrition, and pandemic preparedness are essential to maintaining a strong biomedical innovation ecosystem. We applaud Senator Markey for underscoring the importance of timely, robust funding to advance research and fuel the innovation economy in Massachusetts and across the country. We urge Congress and this administration to prioritize innovative research funding for activities that help bring biomedical innovations out of the lab and into the market.”
“We believe in the value of strong manufacturing in America, and we're very happy that that sentiment is more widely held today than it was just a decade ago. But the financial impact of these tariffs on American manufacturers is stark. Especially for small and mid-sized companies,” said Matthew Boyd, Chief Commercial Officer at Boyd Biomedical. “The tremendous biomedical innovation we create here in Massachusetts is not a valve you can turn off and then expect to turn back on. The consequences of these cuts to federally funded biomedical research will have a decades-long impact on biomedical innovation.”
“Even if some of these actions are reconsidered by the administration or blocked by courts, the current uncertainty and the possibility of some of these actions being implemented will delay life-saving therapies from getting into patients by delaying innovation,” said Dr. Girija Goyal, Ph.D., Principal Scientist at the Wyss Institute.
On March 26, Senator Markey hosted a virtual office hours meeting with Congressman McGovern, food security advocates and food banks, and hundreds of constituents on the importance of protecting SNAP and other essential food security benefits for people in Massachusetts. Earlier that month, Senator Markey led members of the Massachusetts delegation in a joint statement blasting the Trump administration's cuts to the National Institutes of Health. Also in March, Senator Markey hosted a town hall in Malden, Massachusetts to hear directly from constituents about their concerns about what President Trump and DOGE would mean for their health care and Social Security. In February 2025, Senators Markey, Warren and Schumer demanded that the Trump administration, Elon Musk and DOGE make no cuts to Medicaid or Medicare and to end DOGE’s unauthorized access to sensitive health information.
###
